Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 8/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093575 | 0.87 | ADRA1A (0.63) | ADRA1AADRA1DKCNH2TACR1ADRA1B | |
| SCHEMBL11385249 | 0.80 | HTR2C (0.47) | ADRA1AHTR2CDRD2GRM2PRKDC | |
| SCHEMBL3664510 | 0.75 | HTR2C (0.42) | ADRA1AHTR2CDRD2GRM2 | |
| SCHEMBL11375240 | 0.74 | HTR2C (0.46) | HTR2CDRD2GRM2 | |
| SCHEMBL4088031 | 0.73 | ADRA1A (0.59) | ADRA1AADRA1DKCNH2TACR1ADRA1B | |
| SCHEMBL3662919 | 0.72 | HPGD (0.46) | — | |
| SCHEMBL1065758 | 0.71 | HTR2C (0.77) | HTR2CDRD2GRM2 | |
| SCHEMBL15335808 | 0.69 | HTR2C (0.64) | HTR2CDRD2GRM2 | |
| SCHEMBL9230752 | 0.69 | DRD2 (0.64) | HTR2CDRD2GRM2 | |
| SCHEMBL2532290 | 0.68 | HTR2C (0.72) | HTR2CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288424-B2 | Substituted tetrahydroimidazopyridine compounds and the use thereof in the treatment of pain and other conditions | GRUENENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | HRH4, TRPV1, QDPR | ADRA1A 517/4885ADRA1D 269/4885HTR2C 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.